Industry demand<\/a> for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. Meeting this demand requires cold-chain expertise to maintain product quality and safety from manufacturing to patient.<\/p> \u201cWe have aligned our investments with our Healthcare customers\u2019 specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,\u201d said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS. \u201cThis effort \u2013 and all of our work in healthcare logistics \u2013 extends from a deep understanding that we\u2019re doing more than moving packages. We are helping patients access the medications and treatments they need.\u201d<\/p> Single Provider, Total Control: Integrated Freight Cross-Docks Reduce Risk<\/b><\/p> Rise of Advanced Therapies Accelerates Demand for Precision Cold-Chain Solutions<\/b><\/p> The rapidly growing biologics pipeline is increasing complexity across cold-chain logistics. According to PharmaSource, roughly one in three newly approved drugs today is a biologic more than 85% of those requiring temperature-controlled handling<\/a>.<\/p> As therapies like cell and gene treatments, mRNA platforms and GLP-1 injectables come to market, healthcare supply chains are becoming more complex and risk-sensitive. Temperature excursions are a key driver of that risk, with cold-chain failures estimated to cost up to $35 billion annually and, according to WHO, contributing to up to 50% of global vaccine waste.<\/a><\/p> \u201cBiologics and personalized treatments are driving better, more targeted care for patients,\u201d said John Bolla, President of UPS Healthcare. \u201cThese investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.\u201d<\/p> Acquisition to Advantage: Investments Are Scaling Complex Healthcare Logistics<\/b><\/p> UPS\u2019s cross-dock expansion builds on a long-term investment in complex healthcare logistics, strengthened through acquisitions including Bomi Group<\/a>, Frigo Trans and BPL<\/a> in Europe and Andlauer Healthcare Group<\/a> in North America. More recently, UPS expanded its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows<\/a>, as South Korea imported nearly $9.7 billion in pharmaceutical products in 2025<\/a>, according to Observatory of Economic Complexity data.<\/p> The result is a more responsive supply chain that keeps high-value, time- and temperature-sensitive healthcare shipments moving seamlessly across air, ocean, ground and final mile. As demand grows, UPS\u2019s integrated network is built to manage this complexity today and scale for what\u2019s ahead.<\/p> About UPS<\/b><\/p> UPS (NYSE: UPS) is one of the world\u2019s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, \u201cMoving our world forward by delivering what matters,\u201d the company\u2019s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. More information can be found at www.ups.com<\/a>, about.ups.com<\/a> and investors.ups.com<\/a>.<\/p> About UPS Healthcare<\/b><\/p> UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 19.2+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS\u00ae Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Visit Healthcare.ups.com<\/a> for more information.<\/p> Sources:<\/b> Growth Market Reports; PharmaSource; Westwell Lab; World Health Organization; Observatory of Economic Complexity.<\/p>![](\"https:\/\/mms.businesswire.com\/media\/20260622325874\/en\/1697328\/22\/UPS_logo.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260622325874\/en\/1697328\/21\/UPS_logo.jpg\"){kind=logo}
<\/a>